Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer

Advances in precision medicine have led to many changes in drug development for non-small cell lung cancer (NSCLC). Since the landmark IPASS study for Epidermal Growth Factor Receptor (EGFR)-mutant NSCLC, [1] many more molecular subtypes of NSCLC are being recognized, with testing of their complementary targeted therapies. With improvement in assay technology such as next-generation sequencing, NSCLC is subdivided into many smaller subgroups. As these molecular subtypes have low prevalence, traditional randomized controlled trials (RCTs) may neither be feasible nor will provide timely results.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research